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Abstract
Benign enlargement of the prostate, also referred to as benign prostatic hyperplasia, is a common
condition in men. Because enlarged prostate (EP) was viewed historically as a symptomatic
condition, management of voiding symptoms with α-blockers was often the goal of therapy.
However, it is now recognized that EP is a progressive disorder, which may be complicated by
acute urinary retention and which may eventually require EP-related surgery. The 5α-reductase
inhibitors decrease dihydrotestosterone levels, which slow disease progression by causing
regression of the prostate epithelial cells. These agents are considered disease modifying, and they
may reduce the progression of prostate enlargement. This article reviews evaluation, diagnosis, and
treatment strategies for EP, and it provides a practical algorithm for management of patients with
EP.
Background
Review
Benign enlargement of the prostate, also referred to as
benign prostatic hyperplasia (BPH), is a common occur-
rence in aging men. During the past decade, the role of
primary care physicians (PCPs) in managing enlarged
prostate (EP) has increased considerably. This is largely
because men who suffer from bothersome symptoms
associated with EP typically present to their PCPs for ini-
tial treatment. Data from the National Institutes of Health
suggest that at least 6.3 million men in the United States
aged between 50 and 79 years may be affected by EP,
accounting for 4.5 million doctor visits with "hyperplasia
of the prostate" as the primary diagnosis [1]. Although
diagnostic and treatment recommendations are available
for urologists [2], no guidelines have been specifically
designed to guide PCPs in the diagnosis and management
of EP. A survey found that two thirds of PCPs have only
rarely or never used the American Urological Association
Symptom Index (AUA-SI) – an index that provides a valid
measure of a patient's symptom severity over time (based
on 7 questions scored on a 0–4 scale) – when diagnosing
EP [3]. Additionally, PCPs prescribed α-blockers more fre-
quently than 5α-reductase inhibitors (5ARIs), even
though 5ARIs have been shown to be more effective in
management of disease progression of the prostate over
time.
Because EP was viewed historically as a symptomatic con-
dition, management of voiding symptoms was often the
goal of therapy, and as such, α-blockers were advocated as
primary therapy. However, today it is recognized that EP
is a progressive disorder that may be complicated by acute
urinary retention (AUR) and may eventually require EP-
related surgery. The 5ARIs are considered disease-modify-
ing agents because they work by decreasing dihydrotesto-
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sterone (DHT) levels, which slow disease progression by
causing regression of the prostate epithelial cells. These
agents also relieve voiding symptoms, improve peak uri-
nary flow rate, and decrease risk of complications associ-
ated with EP [4,5]. The AUA guidelines recommend use of
5ARIs to prevent disease progression in men with EP [2].
Clinicians need to be aware of current treatment recom-
mendations to appropriately manage patients with EP,
thus creating the need to disseminate practical guidance
tools. This article reviews evaluation, diagnosis, and treat-
ment strategies for EP, and it provides an algorithm for
management of patients with EP.
Identification of the patient with enlarged prostate
Enlargement of the prostate becomes more common as
men age, occurring in more than half of those aged
between 50 and 60 years. Other risk factors that have been
reported for enlarged prostate include nationality and
marital status. Clinical manifestations of EP range from
various degrees of lower urinary tract symptoms (LUTS) to
AUR and renal failure. Clinically, patients are usually
identified by the presence of LUTS, by prostate enlarge-
ment found on digital rectal examination (DRE), or by
elevated prostate-specific antigen (PSA) measurement
during a routine examination.
Because patients are often embarrassed to discuss prostate
symptoms with physicians, LUTS may persist for years
before individuals seek consultation. Men also may con-
sider changes in urinary function to be a normal part of
the aging process, or they may be reluctant to discuss
symptoms because of a fear of EP-related surgery. Addi-
tionally, LUTS are not specific to EP (Table 1). Differential
diagnosis of LUTS may include other urologic and nonu-
rologic conditions, medications that increase obstructive
urinary symptoms, obesity, cigarette smoking, regular
alcohol consumption, and elevated blood pressure [6,7].
Thus, differential diagnoses must be critically evaluated
when examining patients with LUTS.
A comprehensive evaluation is necessary to confirm a
diagnosis of EP. The AUA guidelines recommend a careful
medical history, symptom assessment using the AUA-SI
score or the BPH-impact index, physical examination, uri-
nalysis, and subsequent serum PSA test in appropriate
patients to rule out cancer [2]. Although initial evaluation
does not include routine serum creatinine monitoring,
this measurement may be useful to exclude other causes
of renal insufficiency. Presence of "alarm symptoms,"
such as occurrence of EP in men aged 45 years or younger,
refractory retention, persistent gross hematuria, bladder
stones, renal insufficiency, abnormally high PSA levels,
and recurrent urinary tract infections (UTIs), may require
more immediate management [8].
Prostate size should be evaluated when deciding if and
how to treat. Accurately estimating prostate size and vol-
ume may be challenging with DRE, particularly in men
with a larger prostate [9]. Underestimation of prostate size
could have important ramifications, including inappro-
priate management and disease progression. As a general
guideline, greater than 2-finger widths (or 2.5 for smaller
fingers) diameter would indicate EP (prostate volume >
30 mL) [8].
Assessing symptoms
Patient perception of bothersome symptoms is an impor-
tant consideration in management of EP [2]. Data accu-
mulated over the past decade clearly show that EP is a
progressive disorder, which may be associated with
increasingly bothersome symptoms affecting quality of
life (QOL) [10]. Progression indicators may include dete-
rioration in LUTS, increased prostate size, reduced urinary
flow rate, bladder complications, hematuria, and
increased AUR risk. Although AUR is not life threatening,
it is a serious QOL issue for patients [11]. Consequently,
prevention of AUR is desirable for men with EP, particu-
larly those with risk factors such as moderate to severe
LUTS and poor urinary-flow rates [12].
An epidemiologic study evaluated progression of BPH in
over 2000 men aged 40 years or older [10]. After a 6-year,
longitudinal follow-up, median peak urinary-flow rate
decreased 2.1% each year. Peak urinary-flow rate declined
more rapidly in men with increasing baseline age, prostate
volume, and symptom severity. The largest decline in
peak urinary-flow rate occurred in men aged 70 years or
Table 1: Conditions potentially associated with lower urinary 
tract symptoms in men [6,7]
Urologic and nonurologic conditions
• Prostate cancer
• Prostatitis
• Bladder cancer
• Bladder stones
• Overactive bladder
• Interstitial cystitis
• Diabetes mellitus
• Parkinson's disease
• Congestive heart failure
• Lumbosacral disc disease
• Multiple sclerosis
• Spinal cord injury
• Stroke
Medications
• Tricylic antidepressants
• Anticholinergic agents
• Diuretics
• Narcotics
• First-generation antihistamines
• DecongestantsOsteopathic Medicine and Primary Care 2007, 1:11 http://www.om-pc.com/content/1/1/11
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older and in those with a baseline rate of 10 mL/sec. Addi-
tionally, there was a slow but progressive increase in uri-
nary symptom severity during 42 months of follow-up
[13], with the greatest increases in symptom severity in
men older than 60 years of age as compared with men in
their 40 s. Symptom progression was evident because
14% and 22% of men who had mild symptoms at base-
line reported moderate to severe symptoms after 18 and
42 months, respectively. Among men with none to mild
symptoms at baseline, AUR incidence increased from 2.6/
1000 person-years among men aged 40 to 49 years to 9.3/
1000 person-years among men aged 70 to 79 years. In
those who had moderate to severe symptoms at baseline,
AUR incidence increased substantially from 3.0/1000 per-
son-years in men aged 40 to 49 years to 34.7/1000 per-
son-years in men aged 70 to 79 years. Additionally, men
with decreased urinary-flow rate (< 12 mL/sec) at baseline
had a 4-times increased risk for AUR compared with those
with higher urinary flow rates (> 12 mL/sec). Men with a
prostate larger than 30 mL at baseline had a 3-times
increased AUR risk. Therefore, disease progression is
clearly associated with increased AUR risk.
Prevention of AUR progression is desirable because pros-
tatectomy resulting from AUR is associated with increased
morbidity and mortality [12]. In the Baltimore Longitudi-
nal Study of Aging, men with EP and obstructive symp-
toms were up to 8 times more likely to require
prostatectomy within 10 years than men of the same age
without EP [14]. Advancing age also increased the 10-year
probability for prostatectomy (Figure 1).  The 10-year
probability for EP-related surgery was highest (34%) in
men aged 70 years or older with EP and obstructive symp-
toms. Progression of AUR and the "threat" of eventual EP-
related surgery is a major concern for patients. A survey
conducted in Canada found that nearly 60% of men with
EP were concerned about developing AUR, and that
nearly 70% were significantly concerned about the need
for EP-related surgery [11]. Catheter insertion for AUR
also was considered extremely detrimental to QOL.
Medical management of the enlarged prostate: disease 
modification
The goals of EP management should include disease mod-
ification and treatment of bothersome symptoms.
Depending on size of prostate and symptoms, treatment
options may include watchful waiting (ie, patient moni-
tored by physician with no active intervention), symptom
management, or disease modification (Figure 2).
In the past, treatment primarily focused on symptom
management with anticholinergic agents or α-blockers.
Patients who suffer from urge incontinence resulting from
overactive bladder may be treated with anticholinergic
agents (eg, oxybutynin, tolterodine, solifenacin). For
patients with obstructive symptoms resulting from EP, α-
blockers (eg, terazosin, doxazosin, tamsulosin, alfuzosin)
could improve urinary flow rates. The α-blockers target
smooth muscle receptors in the prostate and bladder neck
by relaxing muscle fibers, and thus making it easier to uri-
nate. All α-blockers are similarly efficacious at improving
urinary flow rates by 15% to 30% although tolerability
profiles may differ among agents [15]; adverse effects may
include orthostatic hypertension, dizziness, and ejacula-
tory problems. Anticholinergics and α-blockers are con-
sidered symptom modifying because they do not affect
the natural course of the disease.
Unlike symptom-modifying agents, 5 ARIs inhibit the 5α-
reductase enzymes responsible for the conversion of testo-
sterone to DHT. The 5 ARIs decrease DHT levels, slowing
Goals of therapy for patients diagnosed with enlarged pros- tate Figure 2
Goals of therapy for patients diagnosed with 
enlarged prostate. (adapted from reference 8, with per-
mission). 5 ARIs = 5α-reductase inhibitor; EP = enlarged 
prostate.
Bothersome Symptoms
• Treat Bothersome Symptoms
(α-blockers/anticholinergics)
• Watchful Waiting
• Advice on Lifestyle, Review of
Current Medication, Assurance 
No EP
No Bothersome Symptoms
• Modify Disease Progression
(5ARIs, combination therapy)
• Treat Bothersome Symptoms
(α-blockers/anticholinergics,
combination therapy, 5ARIs)  
• Watchful Waiting
• Advice on Lifestyle, Review
of Current Medication,
Reassurance 
• Modify Disease Progression
(5ARIs) in Select High-Risk
Individuals 
EP
Prostate enlargement contributes to risk of BPH-related sur- gery [14] Figure 1
Prostate enlargement contributes to risk of BPH-
related surgery [14]. BPH = benign prostatic hyperplasia.Osteopathic Medicine and Primary Care 2007, 1:11 http://www.om-pc.com/content/1/1/11
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the disease process and causing shrinkage of prostate epi-
thelial cells. 5 ARI therapy is considered disease modify-
ing because it treats the underlying cause of the disease.
Dutasteride and finasteride are the 5 ARIs currently avail-
able in the United States, and both agents effectively
relieve symptoms and prevent disease progression in men
with EP. Dutasteride inhibits both type-1 and type-2 iso-
forms of the 5α-reductase enzyme, resulting in greater
than 90% suppression of DHT [16], whereas finasteride
only inhibits the type-2 isoenzyme, reducing DHT levels
by 45% to 85% [17]. Even though adverse effects on sex-
ual function (eg, impotence, decreased libido) have been
reported by patients on 5 ARIs, they are typically reversi-
ble and, after 6 months, no more common than with pla-
cebo [18].
The landmark Medical Therapy of Prostatic Symptoms
(MTOPS) study showed that treatment with a 5 ARI signif-
icantly reduced the rate of AUR and prevented progression
of EP [4]. In this 4.5-year, double-blind, placebo-control-
led trial, 3047 men with symptomatic BPH were rand-
omized to receive doxazosin or finasteride, alone or in
combination, to evaluate delay or prevention of clinical
progression of BPH. Overall clinical progression, defined
by a composite end point of a 4-point or greater increase
in AUA-SI score above baseline, AUR, urinary inconti-
nence, renal insufficiency, or recurrent UTI, was 17% with
placebo, 10% with doxazosin (P < .001), 10% with finas-
teride (P  = .002), and 5% with the combination (P <
.001). The rate of AUR was significantly lower in both the
finasteride (68% risk reduction; P = .009) and the combi-
nation groups (81% risk reduction; P < .001) compared
with placebo. Finasteride (64%) and combination ther-
apy (67%) significantly reduced risk of invasive therapy (P
< .001 compared with placebo for both groups). Although
doxazosin delayed time to AUR, it did not significantly
reduce the cumulative incidence of AUR or invasive ther-
apy, when compared with placebo.
In an evaluation of 4325 men with clinical BPH with
moderate to severe symptoms, treatment with dutasteride
for 24 months reduced serum DHT from baseline by a
mean of 90.2% (P < .001 compared with placebo) [5].
Compared with placebo, dutasteride reduced total pros-
tate volume from baseline by 25.7% at 24 months, transi-
tion zone volume by 20.4%, and symptom score by 4.5
points, and it increased maximal flow rate by 2.2 mL/s (P
< .001). The efficacy of dutasteride was further evaluated
in a 2-year, open-label extension of 3 phase III rand-
omized studies [19]. After 48 months, the dutasteride/
dutasteride combination group experienced improve-
ment in symptoms (AUA-SI score decreased 6.5 points;P
< .001), increased urine flow by 2.7 mL/s (Qmax; P = .042),
and reduced prostate volume by 27.3% (P < .001) from
baseline compared with the placebo/dutasteride group. In
the Proscar Long-term Efficacy and Safety Study, which
evaluated the efficacy of finasteride compared with pla-
cebo in 3040 patients with BPH, prostate volume
decreased by 18% in the finasteride-treated patients com-
pared with a 14% increase in the placebo group [20].
Patients receiving finasteride also experienced improve-
ment in voiding symptoms and peak urinary flow rate
compared with placebo. These findings support the AUA
recommendation of using 5 ARIs for long-term disease
management in patients with LUTS and with evidence of
EP [2].
Treatment guidelines
Figure 3 provides a practical algorithm for treatment of
EP. For men with a smaller prostate (< 30 mL) and no
bothersome symptoms, advice on lifestyle modifications
(eg, weight loss, restricting fluids at night), review of cur-
rent medications, and watchful waiting are recom-
mended. The AUA guidelines advocate watchful waiting
for patients with mild (AUA-SI ≤ 7), moderate, or severe
symptoms (AUA-SI ≥ 8) who are not bothered by their
symptoms [2]. For men with a smaller prostate (< 30 mL)
who experience bothersome symptoms, symptomatic
treatment with α-blockers (and/or anticholinergics) may
be beneficial. Vasodilatory adverse events, such as dizzi-
ness, should be monitored when initiating α-blocker ther-
apy.
For men with EP (≥ 30 mL) and no bothersome symp-
toms, the AUA guidelines recommend use of 5 ARIs to
prevent disease progression, although watchful waiting
Practical algorithm for management of patients with enlarged  prostate associated with bothersome symptoms [8] Figure 3
Practical algorithm for management of patients with 
enlarged prostate associated with bothersome symp-
toms [8]. 5 ARI = 5α-reductase inhibitor; DRE = digital rec-
tal exam; PSA = prostate-specific antigen.Osteopathic Medicine and Primary Care 2007, 1:11 http://www.om-pc.com/content/1/1/11
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may be considered [2]. For men with EP (≥ 30 mL) and
bothersome symptoms, a 5 ARI should be used to shrink
the prostate, thereby improving urinary symptoms, and
reducing AUR risk and the need for subsequent EP-related
surgery. For the long term, some of these patients may be
managed with a 5 ARI alone. An α-blocker (and/or anti-
cholinergics) may be prescribed for patients who experi-
ence particularly bothersome symptoms. Combination
therapy with an α-blocker (for early symptom reduction)
and 5 ARI (for long-term disease management) is most
appropriate in men who are symptomatic and who have a
high risk for progression (ie, enlarged prostate, age > 70
years, high symptom score) [2]. For patients on combina-
tion therapy, the αblocker may be discontinued in the
majority of men once the therapeutic efficacy of the 5 ARI
is confirmed (typically within 6 to 9 months) [21,22]
although some individuals may benefit from continua-
tion of combination therapy. Even though the AUA guide-
lines do not provide specific recommendations for follow-
up, patients undergoing treatment for EP should be peri-
odically assessed for disease progression [8]. Urologic
referral may be indicated for patients with disease progres-
sion while on 5 ARI therapy, men with suspected malig-
nancy based on elevated PSA or physical examination, or
individuals experiencing gross hematuria.
Conclusion
Benign enlargement of the prostate is a common condi-
tion. As the disease progresses, LUTS increase and associ-
ated complications become more common. Current
guidelines for management of EP emphasize the use of 5
ARIs either alone or in combination with an α-blocker.
The use of α-blockers afford symptom relief, but they do
not affect disease progression. The 5 ARIs provide sympto-
matic relief, reduce prostate volume, and slow the disease
process by shrinking prostate epithelial cells. Initiation of
5 ARI therapy in symptomatic men with EP is a reasonable
approach to disease management, which may prevent
long-term negative consequences.
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